STOADA · Synthesis of Targeted Organometallic Anticancer Drugs and their mode of Action
FP7 — People (Marie Curie Actions)
- Duration
- 2009-05-01 → 2010-02-28
- EU contribution
- €189,163
- Participants
- 1
- Scheme
- MC-IIF
Lines connect the coordinator with its partners.
Results in brief
Synthesis of targeted organometallic anticancer drugs and their mode of action
New hybrid complexes composed of ruthenium(II)-arene units with curcumin and pta have beenprepared and evaluated for their medicinal (anticancer) properties. These compounds were characterised by NMR spetroscopy, elemental analyses and mass spectrometry. Biological studies of these compounds on the A2780 and A2780cisR cancer cell lines reveal moderate activity. Screening for enzymatic inhibition of the physiologically dominant carbonic anhydrase isozymes show that the compounds are modest inhibitors. The results obtained in this project provide an opening towards the estimation of possibility of using ruthenium(II)-curcuminate complexes as possible anticancer drugs. As the project has been ended abruptly due to the return of the fellow to India with a permanent position in a leading educational research institute it has been foreseen that it will open a fruitful collaboration between coordinator and IIF research fellow to investigate this area in depth in the near future.
Data: CORDIS, © European Union
Project objective
The project is designed to study a new class of ruthenium antimetastasis compounds, which provides a flexible scaffold onto which various groups of known biological function can be grafted, in order to identify the mechanism of antimetastasis action and obtain superior compounds. In addition, targets will be identified from these compounds using an innovative bio-analytical method. The generic compound which will be used for the study are based on the general structure, Ru(η6-arene)Cl2(pta), and biologically active groups with known therapeutic function, e.g. that induce cell cycle arrest, will be tethered to the arene ring or attached via the ruthenium centre. Key protein targets will then be identified by laser ablation inductively coupled plasma mass spectrometry (ICP-MS). The influence of the inhibitors will be studied and the effect on drug efficacy explored. Drug binding sites will be identified using a mass spectrometric bottom-up or top-down methods which will be very much useful in directing future drug design.
Original text from CORDIS.
Participants
- ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE · LausanneCoordinatorSwitzerland
Links
Data: CORDIS, © European Union